Navigation Links
DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Date:4/16/2008

SAN MATEO, Calif., April 16 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol, without change.

IMPACTS is a Phase II multi-center clinical trial evaluating the safety and effectiveness of intravenous A-001 (varespladib sodium) in preventing the development of acute chest syndrome in hospitalized sickle cell disease patients. Enrolled patients are at-risk for acute chest syndrome based on the combination of pain (vaso-occlusive crisis), fever, and elevated serum level of the enzyme (secretory phospholipase).

"We are pleased with the DSMB's response and look forward to continuing the A-001 trial under our original protocol," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "Treatment options are limited for this important patient population and we believe a drug that provides an opportunity for early intervention would help address a significant unmet medical need."

"Today's announcement marks another exciting milestone for Anthera," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "Over the past few months, we've also made significant progress in our A-002 program for cardiovascular disease. In February, we completed our end of Phase II meeting with the FDA. In early April, we completed a pre-submission meeting with European Medicines Agency (EMEA). Presently, we are preparing to submit our registration protocols to FDA as part of the Special Protocol Assessment process."

About A-001

A-001 is a poten
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
2. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
3. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
4. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
5. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
6. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
7. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
8. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... ANAHEIM, Calif. , July 14, 2014  Mallinckrodt ... (NASDAQ: QCOR ) today announced that the registration ... Exchange Commission ("SEC") by Mallinckrodt plc on May 16, 2014 ... proxy statement of Mallinckrodt and Questcor that also constitutes a ... The registration statement on Form S-4 is available on the ...
(Date:7/14/2014)... BEIJING , July 14, 2014 Sinovac Biotech Ltd. (NASDAQ: ... China , announced today that it will hold its 2014 ... Beijing Time. The meeting will be held at No. 39 Shangdi Xi ... record as of July 9, 2014 will be eligible to vote and ... is to approve the re-election of Weidong Yin , Yuk ...
(Date:7/14/2014)... and LONDON , July 14, 2014 ... IXICO plc (AIM: IXI) jointly announced today the formation ... companies. Dr. Edward Ashton , Ph.D., chief scientific ... have seven members. "The formation of this ... the international commercial and operational alliance we signed with ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7Sinovac Schedules 2014 Annual Meeting of Shareholders 2Sinovac Schedules 2014 Annual Meeting of Shareholders 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9
... by genomics, SAN DIEGO, April 14 ... Therapeutics, Inc. (CTI) (Nasdaq,and MTAX: CTIC), presented data ... patients more likely to respond to treatment with ... for,Cancer Research (AACR) annual meeting. These findings will ...
... April 13 Researchers from the,Barbara Ann ... findings,showing that adding curcumin or resveratrol to ... growth of chemo-resistant colon cancer,cells. The poster ... Cancer Research (AACR) Annual Meeting in San ...
Cached Medicine Technology:New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 2New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 3New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 4New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 5Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
(Date:7/14/2014)... July 14, 2014 BCC Research ... SYNTHETIC BIOLOGY: GLOBAL MARKETS , the global ... nearly $11.9 billion in 2018, with a five-year ... products account for the fastest growing segment, with ... Synthetic biology-enabled products in the pharmaceutical/diagnostics, chemical, energy, ...
(Date:7/14/2014)... The Encino cosmetic dentist at Encino ... and porcelain veneers. These restorations are an excellent alternative ... greater loss of healthy tooth tissue. They work similarly ... on the tooth. Encino dentist Dr. Mastour and his ... they offer the most appropriate treatment recommendations for each ...
(Date:7/14/2014)... Gray HealthDay Reporter ... suggests that a faltering sense of smell might signal ... inexpensive, low-tech smell test could spot who needs more ... the decreased ability to identify odors was associated with ... Alzheimer,s disease. "We,re trying to be able to ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July ... linked to multiple health issues, but dementia isn,t one of ... widowhood may even delay dementia, the researchers found. "For ... was associated with a later age of developing full-blown dementia ... Bryan Woodruff. Woodruff, an assistant professor of neurology ...
(Date:7/14/2014)... Skin M.D. by ... on Monday, July 14th, located at 45 East ... last all week through Saturday, July 19th, with ... welcomed to attend. The business is owned by ... anti-aging, weight loss services, and sells high-end industry ...
Breaking Medicine News(10 mins):Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3
... hunger strike to protest against the raising of the Narmada ... attending on her Sunday. // ,"Medha Patkar has ... doctor at the All India Institute of Medical Sciences (AIIMS) ... ,AIIMS medical superintendent D.K. Sharma said that Patkar's ...
... strapped for cash are planning on letting go of staff and ... Hospital in Wolverhampton, a hospital in such a crisis which has ... hoping to save about ?2.5 million a year. The management hope ... medical secretary bill by sending voice recordings over the internet to ...
... a Melbourne study australians go to hospitals with injuiries due ... latest issue of the Medical// Journal of Australia. ... to falls of all hospital cases. ,Associate Professor ... Centre led the study and incorporated a falls prevention ...
... diet can influence corrective behaviour in prisoners.// ... product of poor nutrition was tested in a prison ... less violent when put on a diet rich in ... paper titled “Seafood Consumption and Homicide Mortality”, raised this ...
... UK has fallen to its lowest levels since such records ... Suicide Prevention Strategy. The report also shows //a drop in ... well as a decline in the number of suicides among ... major cause of preventable death in England and elsewhere. At ...
... chemicals that could trigger inflammation leading to deterioration of ... the crucial link between obesity and heart disease. ... that fat cells lying close to blood vessels in ... influence biological processes within the body, reported the online ...
Cached Medicine News:
... an 125I radioimmunoassay designed for,in ... quantitative,measurement of estradiol in serum, ... in girls,and gynecomastia in men, ... amenorrhea. It is,also intended for ...
... determination of Estradiol (E2) concentration in human serum ... hormone with a phenolic A ring. This ... It is the most potent natural Estrogen, ... smaller amounts by the adrenal cortex, and the ...
... is the most potent, naturally secreted estrogen ... the ovary [1]. In the ovary, estradiol ... estrone, a less potent estrogen derived from ... many body tissues. In men, small amounts ...
... VITROS ECi brings true automation and ... testing. Highly sensitive assays for thyroid, ... bone metabolism testing are currently available, ... The VITROS ECi can simultaneously process ...
Medicine Products: